Suppliers and packagers for generic pharmaceutical drug: LATANOPROST; NETARSUDIL DIMESYLATE

LATANOPROST; NETARSUDIL DIMESYLATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259	NDA	Alcon Laboratories, Inc.	70727-529-25	1 BOTTLE, PLASTIC in 1 CARTON (70727-529-25) / 2.5 mL in 1 BOTTLE, PLASTIC	2019-03-12
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259	NDA	Alcon Laboratories, Inc.	70727-529-99	1 BOTTLE, PLASTIC in 1 CARTON (70727-529-99) / 2.5 mL in 1 BOTTLE, PLASTIC	2019-03-12

Latanoprost / Netarsudil Dimesylate Supply Chain Analysis

Last updated: February 19, 2026

A robust supply chain for latanoprost and netarsudil dimesylate is critical for the uninterrupted production of glaucoma treatments. Key suppliers for both active pharmaceutical ingredients (APIs) and finished dosage forms are identified, with a focus on geographical distribution, manufacturing capabilities, and regulatory compliance. Market intelligence suggests a concentration of API manufacturers in Asia, while finished product manufacturing is more globally distributed.

What are the primary APIs for these glaucoma treatments?

The primary active pharmaceutical ingredients (APIs) for the specified glaucoma treatments are Latanoprost and Netarsudil Dimesylate.

• Latanoprost is a prostaglandin analog used to treat open-angle glaucoma and ocular hypertension. It lowers intraocular pressure by increasing the outflow of aqueous humor.
• Netarsudil Dimesylate is a Rho-kinase inhibitor and adrenergic receptor antagonist, used to treat open-angle glaucoma and ocular hypertension. It lowers intraocular pressure by increasing uveoscleral outflow and decreasing aqueous humor production.

Who are the key API suppliers for Latanoprost?

Key API suppliers for Latanoprost include manufacturers with established capabilities in complex organic synthesis and adherence to Good Manufacturing Practices (GMP).

• Sun Pharmaceutical Industries Ltd. (India): A significant global pharmaceutical company with substantial API manufacturing capacity. Their facilities are often audited and approved by major regulatory agencies.
• Novartis AG (Switzerland) / Alcon (Switzerland): While primarily a finished product manufacturer, Novartis and its subsidiary Alcon may have internal API production or strong partnerships with contract manufacturers. Alcon, in particular, has a long history in ophthalmology.
• Ajanta Pharma Ltd. (India): Another Indian pharmaceutical company known for its API production, often supplying to both domestic and international markets.
• Teva Pharmaceutical Industries Ltd. (Israel): A large generic pharmaceutical manufacturer with a broad API portfolio.
• Accord Healthcare (UK) / Intas Pharmaceuticals Ltd. (India): Accord Healthcare, part of Intas Pharmaceuticals, is a significant player in the generic API market.

These suppliers typically operate under strict regulatory oversight, including inspections by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Production volumes can vary based on demand and contractual agreements with finished dosage form manufacturers.

What are the key API suppliers for Netarsudil Dimesylate?

The supply chain for Netarsudil Dimesylate is less mature than that of Latanoprost, reflecting its more recent market introduction.

• Gland Pharma Limited (India): Known for its contract manufacturing capabilities, Gland Pharma is a potential supplier for various APIs, including those for specialized ophthalmic drugs.
• Dr. Reddy's Laboratories (India): A major Indian pharmaceutical company with strong R&D and manufacturing expertise, capable of producing complex APIs.
• Divi's Laboratories Limited (India): A significant global producer of APIs and intermediates, often contracted for custom synthesis.
• Lantech Pharmaceuticals (USA): While specific API manufacturing relationships are proprietary, U.S.-based CDMOs with expertise in ophthalmic APIs may be involved.
• Various Contract Development and Manufacturing Organizations (CDMOs) globally, particularly in India, China, and Eastern Europe. These CDMOs specialize in custom synthesis and scale-up for novel or complex molecules.

The sourcing of Netarsudil Dimesylate API may be more consolidated, potentially tied to the original patent holder's manufacturing or development partners.

Which companies manufacture finished dosage forms of Latanoprost?

Finished dosage form manufacturers for Latanoprost are numerous, given its status as a widely prescribed generic medication.

• Alcon Laboratories, Inc. (USA/Switzerland): Market leader in ophthalmology products, producing brand-name and generic ophthalmic solutions.
• Teva Pharmaceuticals USA, Inc. (USA): A major supplier of generic drugs, including ophthalmic solutions.
• Viatris Inc. (USA): Formed by the merger of Mylan and Pfizer's Upjohn, Viatris offers a broad portfolio of generic pharmaceuticals.
• Bausch + Lomb (USA): Another significant player in the eye care market with a range of prescription ophthalmic products.
• Sun Pharmaceutical Industries Ltd. (India): Markets its own finished ophthalmic products.
• Santen Pharmaceutical Co., Ltd. (Japan): Specializes in ophthalmic prescription drugs.
• Apotex Inc. (Canada): A large generic pharmaceutical manufacturer.
• Mylan N.V. (USA) - Now part of Viatris.

These companies utilize sterile manufacturing facilities compliant with FDA, EMA, and other national regulatory body standards. The formulation typically involves sterile, preserved ophthalmic solutions.

Which companies manufacture finished dosage forms of Netarsudil Dimesylate?

The market for Netarsudil Dimesylate finished dosage forms is currently dominated by the innovator company and its licensed partners, reflecting its status as a newer, patented drug.

• Kadmon Pharmaceuticals, LLC (USA) - Acquired by Sanofi: The original developer and manufacturer of Rhopressa® (netarsudil ophthalmic solution). Sanofi now oversees its production and distribution.
• Potential Generic Manufacturers (post-patent expiry): As patents expire, generic manufacturers such as those listed for Latanoprost (Teva, Viatris, Apotex, Sun Pharma, etc.) will likely enter the market, contingent on bioequivalence studies and regulatory approvals. The specialized nature of ophthalmic drug formulation may lead to a smaller initial group of generic entrants compared to Latanoprost.

Manufacturing of Netarsudil Dimesylate involves sterile filling and packaging processes within cGMP-compliant facilities.

What is the geographical distribution of these suppliers?

The geographical distribution of suppliers for latanoprost and netarsudil dimesylate APIs and finished products is a key factor in supply chain resilience and cost.

• API Manufacturing:

  • India is a dominant hub for both Latanoprost and Netarsudil Dimesylate API production due to its established chemical synthesis infrastructure, skilled workforce, and competitive manufacturing costs.
  • China is another significant global supplier of APIs and intermediates, offering a broad range of chemical manufacturing capabilities.
  • Europe (e.g., Switzerland, Germany) is home to some high-value API manufacturers, often focused on niche or proprietary products, and rigorous quality control.
  • North America (USA, Canada) has API manufacturing, but it is often more focused on specialized or patented intermediates and final API steps, or for domestic supply security.

• Finished Dosage Form Manufacturing:

  • North America (USA, Canada) hosts major ophthalmic drug manufacturers, including those with significant R&D and sterile manufacturing operations.
  • Europe (UK, Ireland, Switzerland) also has a strong presence of pharmaceutical manufacturing, with many multinational companies having European production sites.
  • Asia (India, Japan) plays a crucial role, particularly India for its large generic finished product manufacturing sector, and Japan for specialized ophthalmic companies.
  • Latin America (e.g., Brazil) has a growing pharmaceutical manufacturing base, often serving regional markets.

This global distribution necessitates robust logistics, quality assurance across different regulatory environments, and proactive risk management for geopolitical or natural disaster disruptions.

What are the regulatory considerations for these suppliers?

Suppliers for latanoprost and netarsudil dimesylate must adhere to stringent regulatory standards to ensure product safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): All API and finished dosage form manufacturers must comply with cGMP regulations as defined by agencies like the FDA (21 CFR Parts 210 & 211), EMA, and national health authorities. This includes stringent controls over manufacturing processes, facility design, personnel training, quality control testing, and documentation.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API suppliers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the API manufacturing process, facilities, and quality controls, which are reviewed by regulators when assessing a finished drug product application.
• Inspections and Audits: Manufacturers are subject to routine inspections by regulatory authorities (e.g., FDA site inspections) and regular audits by their pharmaceutical clients. Successful audit outcomes are critical for supplier qualification.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, such as ICH Q7 for GMP for APIs, ICH Q1A(R2) for stability testing, and ICH Q11 for development and manufacture of drug substances, is essential for global market access.
• Pharmacopeial Standards: APIs and finished products must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• Environmental, Social, and Governance (ESG) Factors: Increasingly, regulators and customers are scrutinizing suppliers' ESG practices, including environmental sustainability and labor practices.

For Netarsudil Dimesylate, specific regulatory considerations may also include post-market surveillance data and pharmacovigilance related to its unique mechanism of action.

What are the key technological and manufacturing challenges?

Manufacturing of ophthalmic drugs like latanoprost and netarsudil dimesylate presents specific technological and manufacturing challenges.

• Sterility Assurance: Maintaining sterility throughout the manufacturing process, from API synthesis to final filling and packaging, is paramount. This requires validated aseptic processing techniques, sterile filtration, and rigorous environmental monitoring in cleanroom facilities (e.g., ISO Class 5 environments for aseptic filling).
• API Purity and Impurity Control: Both latanoprost and netarsudil dimesylate are complex organic molecules requiring precise synthesis. Controlling process-related impurities and degradation products to very low levels (often ppm) is critical and necessitates advanced analytical methods (e.g., HPLC, GC-MS).
• Formulation Stability: Ophthalmic solutions must remain stable under various storage conditions for their entire shelf life. This includes maintaining chemical stability of the API and physical stability of the formulation (e.g., pH, osmolality, clarity). Preservative systems, if used, must be compatible with the API and packaging.
• Packaging Integrity: Ophthalmic packaging, typically small volume plastic bottles with precise dropper mechanisms, must maintain sterility and prevent contamination over multiple uses. Integrity testing of these closures is crucial.
• Scale-Up Complexity: Transitioning from laboratory-scale synthesis to large-scale commercial API and finished product manufacturing can present challenges in maintaining consistent quality and yield. Process validation is essential.
• Cost of Goods: For generic products like latanoprost, cost-effective manufacturing is vital to compete in the market. Optimization of synthesis routes and efficient production processes are key. For newer drugs like netarsudil, initial manufacturing costs may be higher due to complex synthesis and specialized facilities.

Key Takeaways

• The supply chain for latanoprost and netarsudil dimesylate APIs is largely concentrated in India and China, leveraging established chemical manufacturing infrastructure and cost advantages.
• Finished dosage form manufacturing is more globally distributed, with significant operations in North America, Europe, and Asia.
• Regulatory compliance, particularly cGMP, is a non-negotiable prerequisite for all suppliers, with ongoing inspections and audits being critical.
• Sterility assurance, API purity, formulation stability, and packaging integrity are key manufacturing challenges unique to ophthalmic drug production.
• The market for netarsudil dimesylate finished products is currently controlled by the innovator, but a generic market is anticipated post-patent expiry.

FAQs

1. How does the geographical concentration of API suppliers in Asia impact supply chain risk? Geographical concentration can increase supply chain risk due to potential disruptions from geopolitical instability, natural disasters, or localized regulatory changes. Companies often mitigate this by qualifying multiple suppliers across different regions or by holding higher inventory levels.

2. What are the typical lead times for API and finished product orders? Lead times can vary significantly. API lead times might range from 3 to 9 months, depending on the complexity of the synthesis and current production schedules. Finished product lead times are typically shorter, from 1 to 4 months, assuming API availability and established manufacturing slots.

3. How is the quality of APIs verified from different global suppliers? Quality is verified through a multi-faceted approach including thorough supplier audits, review of DMFs/ASMFs, testing of incoming raw materials and finished APIs against predefined specifications, and ongoing batch release testing by the finished product manufacturer.

4. What is the shelf life typically expected for these ophthalmic solutions? Ophthalmic solutions, including those containing latanoprost and netarsudil dimesylate, generally have shelf lives of 18 to 36 months when stored under recommended conditions. This is determined through extensive stability studies.

5. Are there specific patent considerations that affect the supply of netarsudil dimesylate? Yes, netarsudil dimesylate is a patented molecule. Its supply chain is initially dictated by the patent holder and their exclusive licensees. The introduction of generic versions will be contingent upon patent expiry or successful legal challenges to existing patents.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA website]

[2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA website]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website]

[4] United States Pharmacopeial Convention. (n.d.). USP-NF Online. Retrieved from [USP website]